Profile data is unavailable for this security.
About the company
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company engaged in the discovery, development and commercialization of therapies for the treatment of advanced solid tumors and other major diseases. The Company’s cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Certepetide actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are expected to remain unaffected. The Company’s investigational drug candidate from the CendR Platform, certepetide, holds broader potential to be combined as a co-administration treatment with an array of anti-cancer and diagnostic agents to benefit solid tumor cancer patients.
- Revenue in USD (TTM)1.07m
- Net income in USD-18.24m
- Incorporated1980
- Employees26.00
- LocationLisata Therapeutics Inc110 Allen Road, Second FloorBASKING RIDGE 07920United StatesUSA
- Phone+1 (908) 229-2590
- Fax+1 (845) 818-3588
- Websitehttps://www.lisata.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Outlook Therapeutics Inc | 1.51m | -62.42m | 36.02m | 17.00 | -- | -- | -- | 23.93 | -1.61 | -1.61 | 0.0432 | -0.5973 | 0.0635 | -- | -- | 88,548.23 | -263.36 | -240.08 | -- | -- | 70.78 | -- | -4,146.95 | -22,354.50 | 0.3067 | -200.54 | -- | -- | -- | -- | 17.17 | -- | -- | -- |
| Atossa Therapeutics Inc | 0.00 | -30.18m | 36.17m | 13.00 | -- | 0.7265 | -- | -- | -3.52 | -3.52 | 0.00 | 5.78 | 0.00 | -- | -- | 0.00 | -43.90 | -26.93 | -48.89 | -29.04 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 15.25 | -- | 20.02 | -- |
| Axe Compute Inc | 728.20k | -84.01m | 36.36m | 23.00 | -- | -- | -- | 49.94 | -120.02 | -120.66 | 1.29 | -100.94 | 0.1369 | 1.34 | 2.97 | 31,660.87 | -1,579.84 | -85.09 | -- | -113.42 | 50.24 | 61.31 | -11,536.93 | -1,267.27 | 0.0134 | -0.1392 | -- | -- | -0.2384 | 2.84 | 9.63 | -- | -18.60 | -- |
| PDS Biotechnology Corp | 0.00 | -34.88m | 36.70m | 24.00 | -- | 3.54 | -- | -- | -0.8194 | -0.8194 | 0.00 | 0.1982 | 0.00 | -- | -- | 0.00 | -80.05 | -57.93 | -125.74 | -68.38 | -- | -- | -- | -- | -- | -8.43 | 0.6552 | -- | -- | -- | 12.42 | -- | -- | -- |
| Veru Inc | 0.00 | -19.20m | 36.76m | 20.00 | -- | 0.9901 | -- | -- | -1.21 | -1.20 | 0.00 | 2.31 | 0.00 | -- | -- | 0.00 | -43.95 | -47.51 | -51.96 | -59.79 | -- | -- | -- | -188.81 | -- | -- | 0.00 | -- | -- | -- | 55.53 | -- | -60.02 | -- |
| INmune Bio Inc | 50.00k | -49.89m | 38.28m | 22.00 | -- | 1.51 | -- | 765.66 | -2.14 | -2.14 | 0.0021 | 0.9546 | 0.0012 | -- | 0.0258 | 2,272.73 | -115.83 | -45.54 | -153.59 | -52.16 | -- | -- | -99,774.00 | -19,298.45 | -- | -942.22 | 0.00 | -- | -90.97 | -- | -40.24 | -- | -- | -- |
| Xilio Therapeutics Inc | 31.80m | -58.49m | 39.19m | 64.00 | -- | -- | -- | 1.23 | -0.6571 | -0.6571 | 0.3348 | -0.1562 | 0.3053 | -- | -- | 496,937.50 | -56.14 | -67.88 | -102.68 | -81.71 | -- | -- | -183.90 | -5,578.28 | -- | -2.84 | -- | -- | -- | -- | 23.77 | -- | -45.00 | -- |
| Cypherpunk Technologies Inc | 0.00 | -50.81m | 40.22m | 52.00 | -- | 10.92 | -- | -- | -1.23 | -1.23 | 0.00 | 0.065 | 0.00 | -- | -- | 0.00 | -132.94 | -79.03 | -196.76 | -93.29 | -- | -- | -- | -9,055.53 | -- | -- | 0.00 | -- | -- | -- | 16.74 | -- | -- | -- |
| Lisata Therapeutics Inc | 1.07m | -18.24m | 40.31m | 26.00 | -- | 2.30 | -- | 37.67 | -2.13 | -2.13 | 0.1246 | 1.98 | 0.0357 | -- | -- | 41,153.85 | -60.85 | -44.77 | -71.25 | -49.07 | -- | -- | -1,704.86 | -13,065.70 | -- | -- | 0.00 | -- | -- | -- | 4.10 | -- | -- | -- |
| CEL-SCI Corp | 0.00 | -25.41m | 41.20m | 43.00 | -- | 2.46 | -- | -- | -7.81 | -7.81 | 0.00 | 1.99 | 0.00 | -- | -- | -- | -92.16 | -72.20 | -111.94 | -80.91 | -- | -- | -- | -- | 2.20 | -38.20 | 0.3328 | -- | -- | -- | 7.86 | -- | -57.33 | -- |
| Aligos Therapeutics Inc | 2.65m | -86.46m | 42.52m | 70.00 | -- | 0.5919 | -- | 16.07 | -12.70 | -12.70 | 0.2964 | 11.67 | 0.0267 | -- | -- | 37,800.00 | -87.25 | -60.83 | -111.39 | -72.31 | -- | -- | -3,267.65 | -1,462.14 | -- | -- | 0.002 | -- | -74.60 | -- | -49.65 | -- | -45.83 | -- |
| OS Therapies Inc | 0.00 | -20.26m | 42.96m | 4.00 | -- | 11.16 | -- | -- | -0.9794 | -0.9794 | 0.00 | 0.1415 | 0.00 | -- | -- | 0.00 | -334.55 | -- | -870.52 | -- | -- | -- | -- | -- | -- | -2,674.49 | 0.00 | -- | -- | -- | -37.51 | -- | -- | -- |
| Protext Mobility Inc | 750.00 | -2.21m | 43.08m | 4.00 | -- | -- | -- | 57,435.98 | -0.4692 | -0.4692 | 0.00001 | -0.0102 | 0.0405 | -- | -- | -- | -9,400.97 | -1,587.94 | -- | -- | 86.67 | -530.19 | -232,392.00 | -17,498.83 | 0.0002 | -1.36 | -- | -- | -93.98 | -63.09 | 27.35 | -- | -- | -- |
| ABVC Biopharma Inc | 797.92k | -4.12m | 43.09m | 16.00 | -- | 3.35 | -- | 54.00 | -0.2223 | -0.2223 | 0.0464 | 0.4985 | 0.0448 | -- | 0.408 | 49,870.00 | -24.89 | -105.17 | -42.73 | -217.00 | 0.2469 | 75.19 | -555.90 | -2,124.21 | 0.6241 | -13.71 | 0.0662 | -- | 234.31 | -6.20 | 37.05 | -- | -- | -- |
| CervoMed Inc | 6.16m | -25.58m | 43.67m | 15.00 | -- | 1.68 | -- | 7.09 | -2.87 | -2.87 | 0.6919 | 2.81 | 0.155 | -- | 7.58 | 410,652.00 | -64.37 | -54.89 | -71.42 | -60.99 | -- | -- | -415.36 | -428.45 | -- | -- | 0.00 | -- | 36.29 | -- | -650.08 | -- | -- | -- |
Data as of Feb 13 2026. Currency figures normalised to Lisata Therapeutics Inc's reporting currency: US Dollar USD
7.55%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 239.60k | 2.72% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 123.72k | 1.40% |
| BML Capital Management LLCas of 31 Dec 2025 | 73.35k | 0.83% |
| Geode Capital Management LLCas of 31 Dec 2025 | 64.43k | 0.73% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 54.86k | 0.62% |
| Ground Swell Capital LLCas of 31 Dec 2025 | 38.99k | 0.44% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 30.28k | 0.34% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 14.35k | 0.16% |
| Dimensional Fund Advisors LPas of 31 Dec 2025 | 14.15k | 0.16% |
| Cerity Partners LLCas of 31 Dec 2025 | 12.18k | 0.14% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
